AI filing briefs · archive

8-K filings in November 2024, explained

513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 513 briefs match

newest first · times in ET

PTGXProtagonist Therapeutics, Inc Nov 18, 4:36 PM ET

Protagonist reports positive Phase 3 psoriasis results; earns $165 million milestone

Positive product/contract Written later 1.01 8.01

Protagonist said its Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies of icotrokinra in plaque psoriasis met their primary endpoints. Under a November 13, 2024 amendment to its collaboration with Janssen, the company has earned a $165 million milestone, which it expects to receive in Q1 2025, and the filing states the payment is not refundable. The filing does not provide revenue, profit or guidance figures.

ICONIC-LEAD: 64.7% of patients reached IGA 0/1 at week 16 on icotrokinra vs. 8.3% on placebo; 49.6% reached PASI 90 vs. 4.4% on placebo.
Amendment raised the Phase 3 milestone by $50 million to $165 million and eliminated $35 million and $15 million milestone payments, which accelerates them into the $165 million.
Company expects to receive the $165 million in Q1 2025 and remains eligible for up to $630 million in future milestones plus tiered royalties of 6-10% on worldwide net sales.

Read the filing on SEC.gov ↗

ACMAECOM Nov 18, 4:11 PM ET

AECOM Q4 revenue rises 7% to $4.1 billion; raises dividend 18% and buyback to $1 billion

Positive earnings Written later 2.02 8.01

AECOM reported fiscal fourth-quarter 2024 revenue of $4.1 billion, up 7% from a year earlier, with diluted EPS of $1.25 as reported and adjusted EPS up 26%. It guided fiscal 2025 adjusted EPS to $5.00 to $5.20 and raised its quarterly dividend 18% to $0.26 and its share repurchase authorization to $1 billion, which affects per-share returns for shareholders.

Q4 fiscal 2024 diluted EPS was $1.25 as reported, versus $0.24 a year earlier; adjusted EPS rose 26%
Full-year fiscal 2024 revenue was $16.1 billion, up 12%, and free cash flow was $708 million
Fiscal 2025 guidance includes adjusted EPS of $5.00 to $5.20 and adjusted EBITDA of $1,170 million to $1,210 million
Quarterly dividend raised to $0.26 from $0.22, payable January 17, 2025, to holders of record on January 2, 2025

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.